Peptide Insider

Eloralintide Side Effects: What the Trials Actually Measured

Eloralintide side effects — what the trials actually measured

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-02 · Last updated: 2026-09-07

Eloralintide side effects are already better documented than most peptides ever get: a 263-person, 48-week phase 2 trial published in The Lancet, a 100-person phase 1, and a single-dose study in healthy volunteers — all with placebo controls and published adverse-event rates. The short answer: nausea and fatigue are the two effects that matter, both are clearly dose-dependent, and fatigue — not nausea — is the finding that separates this compound from the GLP-1 family. This page gives you the actual rates, with citations, and flags exactly where the trial data stops applying to a research vial.

Quick Answer: The Most Common Eloralintide Side Effects

In the 48-week phase 2 trial, the two most common adverse events were nausea (11–64% depending on dose, vs 14% on placebo) and fatigue (0–46% by dose, vs 12% on placebo). In the 12-week phase 1 at steadier exposures, GI effects were infrequent — nausea 8%, diarrhea 10%, vomiting 4% — and the most common event was decreased appetite (19%), which is the mechanism doing its job. Most events across both trials were mild; the phase 1 reported no deaths and one serious adverse event judged unrelated to the drug.

★The Documented Experience of 400+ Trial Participants

The most complete “user experience” of eloralintide that exists belongs to the people who took it under observation — 263 in the phase 2, 100 in the phase 1, 48 in the single-dose study. The typical arc: appetite quieted early (decreased appetite was the phase 1’s most common event at 19%), weight moved steadily downward, and the side effects that showed up — nausea and fatigue — tracked the dose, clustering at the higher exposure levels.

How tolerable did participants find it? The phase 1 investigators reported that most adverse events were mild, with no deaths and a single serious event judged unrelated to the drug — and the placebo group reported nausea (14%) and fatigue (12%) too, a baseline most online discussion never subtracts. The Lancet authors’ overall verdict: “generally well tolerated.”

What that experience came with: screening, monitoring, pharmaceutical-grade product from Eli Lilly, and clinician-managed dosing — none of which ships with a research vial.

Compiled from the published trials (PMID 41207310, PMID 41559929, PMID 41109426) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is Eloralintide?

Eloralintide (Eli Lilly’s LY3841136) is a long-acting, selective amylin receptor agonist — a lab-built analogue of the pancreatic fullness hormone amylin, engineered for once-weekly injection (PMID 41109426). In its 48-week phase 2 trial, the top doses produced 20% average weight loss as a standalone compound (PMID 41207310) — territory that previously took a two-drug combination to reach — which is exactly why search interest and research-market listings are arriving at the same time. It is not an approved drug anywhere as of this writing: everything sold under this name outside a trial is research-market material, a distinction that matters more on this page than on most.

How It Works — and Why Selectivity Was the Whole Point

Amylin analogues slow gastric emptying and act on satiety circuits, and their side effects are that mechanism turned up too far. Eloralintide’s design bet was receptor selectivity: in vitro it activates the human amylin 1 receptor about 12-fold more potently than the calcitonin receptor and 11-fold more than the amylin 3 receptor (PMID 41109426). In rat studies, that selectivity translated into significantly less conditioned taste avoidance — the animal proxy for nausea — than cagrilintide, the non-selective amylin agonist it will inevitably be compared with. The human data below is the test of whether that bet paid off.

KEY TAKEAWAY

Eloralintide was built to be the gentler-stomach amylin drug — and at phase 1 exposures the GI numbers were strikingly low. At phase 2’s higher doses, nausea and fatigue still arrived with the milligrams. Selectivity moved the curve; it didn’t delete it.

The Trial Numbers That Matter

Three datasets do the heavy lifting on this page. The phase 2 trial: 263 adults with obesity or overweight, randomized across placebo and six eloralintide arms — 1mg, 3mg, 6mg, 9mg fixed, plus 6→9mg and 3→9mg escalation schedules — once weekly for 48 weeks, published in The Lancet (PMID 41207310). The phase 1 multiple-ascending-dose study: 100 participants over 12 weeks (PMID 41559929). And the single-ascending-dose study in 48 healthy volunteers at 0.04–12mg, published with the discovery work (PMID 41109426). For a compound this new to research-market listings, published placebo-controlled rates at every stage is an unusually strong evidence base — the phase 2 weight-loss curve (9% to 20% by dose, versus 0.4% loss on placebo) is the reason the compound is suddenly everywhere.

Gastrointestinal Side Effects: The Real Rates

The phase 2 numbers, exactly as reported: nausea in 11% (1mg), 13% (3mg), 64% (6mg), 33% (9mg), 54% (6→9mg), and 25% (3→9mg) of participants, versus 14% on placebo (PMID 41207310). Two readings matter. First, the floor isn’t zero: one in seven placebo participants reported nausea with no drug at all, so the attributable share at the lower doses is small to nil. Second, the pattern across dose groups is not a clean staircase — 64% at 6mg fixed against 33% at 9mg fixed — and with only 28 people in the 6mg group, small-sample noise is the likely explanation. We report the numbers as published rather than smoothing them.

The phase 1 tells the other half of the story: at 12 weeks of once-weekly dosing without escalation, GI events were infrequent — diarrhea 10%, nausea 8%, vomiting 4% — with most events mild (PMID 41559929). For an amylin-class compound, single-digit nausea is the headline the selectivity design was aiming for.

PERSONAL OBSERVATION — PI EDITORIAL

Reading the phase 1 and phase 2 side by side, what struck us wasn’t the nausea column — it was how differently the same compound reads at different exposures. The 12-week phase 1 looks like the tolerability story Lilly designed for: nausea 8%, barely above placebo rates elsewhere. The 48-week phase 2 at full doses looks like every other potent weight-loss compound: real GI cost for real weight loss. Both are true; any writeup quoting only one of them is selling you something.

Fatigue: The Side Effect That Sets Eloralintide Apart

The second most common phase 2 adverse event is the one GLP-1 coverage hasn’t trained anyone to expect: fatigue, in 0% (1mg), 13% (3mg), 29% (6mg), 43% (9mg), and 46% (6→9mg) of participants, versus 12% on placebo (PMID 41207310). Unlike the nausea column, this one does climb the dose ladder almost cleanly — at the top doses, roughly two in five participants reported it. Fatigue also appeared in the phase 1 at 11% (PMID 41559929), so it isn’t a one-trial artifact. The abstracts don’t report severity grading or discontinuations specifically for fatigue, so neither will we — but if you’re building an honest mental model of this compound, it’s nausea and tiredness, not nausea alone.

Bar chart of eloralintide phase 2 adverse events by weekly dose arm: nausea 14% placebo, 11% at 1 mg, 13% at 3 mg, 64% at 6 mg, 33% at 9 mg, 54% at 6-to-9 mg escalation, 25% at 3-to-9 mg; fatigue 12% placebo, 0%, 13%, 29%, 43%, 46%, 21% across the same arms.
Chart: nausea and fatigue by dose arm in the 48-week phase 2 trial, plotted from the published rates (PMID 41207310). Fatigue climbs the dose ladder almost cleanly; nausea is noisier — the 6 mg arm (n=28) sits above 9 mg (n=54). Arms are small, so treat single-arm differences with caution.

Injection-Site Reactions

Here’s what the published abstracts do not report: injection-site reaction rates. Neither the phase 2 nor the phase 1 abstract names administration-site events among the most common adverse events (PMID 41207310, PMID 41559929) — which tells you they weren’t a leading category, and nothing more precise than that. Eloralintide is a once-weekly subcutaneous injection like its amylin-family peers, so the standard handling picture applies.

PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING

  • Reconstituted solutions brought to room temperature before use are standard practice in clinical settings
  • Site rotation (abdomen, thigh, upper arm) is how trial protocols manage repeated weekly injections
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
  • Our bacteriostatic water guide covers reconstitution handling in detail

Beyond the Gut: What Else the Trials Recorded

The phase 1’s full most-common list is worth reading precisely, because it’s mundane in an informative way: decreased appetite (19%), headache (12%), fatigue (11%), and COVID-19 (11%) (PMID 41559929). Decreased appetite leading the table is the mechanism working, recorded as an “adverse event” because trial reporting counts everything — and COVID-19 making the list is a reminder that these tables log every medical event during the study window, drug-related or not. On the serious end: the phase 1 reported no deaths and exactly one serious adverse event, judged unrelated to eloralintide; the single-dose study in healthy volunteers logged 16 adverse events across 9 participants, 15 of them mild (PMID 41109426). Cardiovascular events do not appear among the frequent categories in any abstract — and we won’t convert that absence into a safety claim; dedicated outcome data doesn’t exist yet.

When Side Effects Happen — and When They Fade

No published eloralintide data supports a week-by-week side-effect calendar, and anyone offering one made it up. What the trial design does tell you: the phase 2 included two escalation arms (3→9mg and 6→9mg) precisely because amylin-class GI effects concentrate around dose starts and increases, and the phase 1 — where doses were held steady with no escalation — recorded the lowest GI rates of any eloralintide dataset (PMID 41559929). The honest translation: new exposure levels are the risky windows; stable exposure is where the numbers settle. The fatigue signal’s time course hasn’t been characterized in the abstracts at all.

Long-Term Safety: What 48 Weeks Can and Can’t Tell You

The longest published exposure is the phase 2’s 48 weeks in 263 people, with the authors’ summary verdict that eloralintide “was generally well tolerated” (PMID 41207310). That’s meaningful reassurance for the first year — and it is also the entire horizon. This compound entered human testing in 2022 (PMID 41109426); multi-year safety data doesn’t exist because it can’t yet. Phase 3 trials will multiply the participant-years several-fold. Anyone speaking about eloralintide’s five-year profile is forecasting, not reporting.

Who the Trials Excluded

Trial safety numbers describe trial populations. The phase 2 enrolled adults aged 18–75 with a BMI of 30+ (or 27+ with a weight-related comorbidity) and specifically excluded people with type 2 diabetes (PMID 41207310); its typical participant was a 49-year-old woman weighing 109kg. The phase 1 enrolled adults with obesity or overweight averaging a BMI of 32.6 (PMID 41559929), and the single-dose study used healthy volunteers. Every rate on this page was generated in screened, monitored people with clinicians watching — a context no research buyer replicates. That’s not a technicality; it’s the boundary of what these numbers can promise.

Managing and Minimizing Side Effects: What the Trials Did

The trials’ side-effect management was structural: dose selection and escalation scheduling, not add-on fixes. The phase 2 tested two escalation schemes against fixed dosing to map exactly this trade-off (PMID 41207310). The other measurable lever is the one nobody markets: the 1mg group’s nausea (11%) sat below placebo (14%) with 0% fatigue — and delivered 9% weight loss. Lower exposure, fewer effects, less weight change; the trade is visible across the whole dose table. We report all of this as trial design, not as a protocol recommendation — no anti-nausea co-medication scheme appears in any abstract.

Dose and Side Effects: The Correlation Is Measured

This is the rare peptide where the dose–side-effect relationship was plotted in humans across a six-arm design. From 1mg to 9mg weekly: weight loss climbed from 9% to 20%, fatigue climbed from 0% to 43–46%, and nausea rose from 11% into the 25–64% band, noisily (PMID 41207310). The escalation arms landed inside the fixed-dose ranges on both effect and side effect — the 6→9mg arm matched fixed 9mg’s 20% weight loss. The pattern beneath the noise is the same one every compound in this family shows: exposure buys effect and side effect together, and there is no published dose that separates them.

DID YOU KNOW

In rat studies, eloralintide produced significantly less conditioned taste avoidance — the standard animal proxy for nausea — than cagrilintide at comparable weight-loss efficacy (PMID 41109426). That preclinical result is the entire “gentler amylin” thesis, and the phase 1’s 8% nausea rate is the first human evidence for it.

Eloralintide Alone vs Stacked: What the Data Covers

Here eloralintide differs sharply from cagrilintide, whose stacked profile (CagriSema) is documented in a 3,417-person phase 3. For eloralintide, no combination trial results have been published — every published rate on this page comes from eloralintide alone. That means the stacks research forums are already discussing — eloralintide plus retatrutide, plus tirzepatide, plus anything — have no published human safety data at all. The monotherapy numbers cannot be borrowed for a stack: cagrilintide’s data shows what stacking an amylin with a GLP-1 did to GI rates there (41–63% alone became 79.6% combined), and that’s the nearest documented analogy, not a measurement. Our GLP-3 sourcing guide and retatrutide vendor page cover that family separately.

How Eloralintide Compares to Cagrilintide and the GLP-1s

No head-to-head human trial exists, so every comparison is cross-trial — different populations, durations, and reporting, which is a real limitation. With that flag planted: eloralintide’s top fixed dose reported 33% nausea alongside 20% weight loss at 48 weeks (PMID 41207310); cagrilintide’s top dose reported 47% nausea alongside 10.8% weight loss at 26 weeks — see our full cagrilintide side effects breakdown. The amylin class as a whole is being positioned as the better-tolerated alternative to high-dose GLP-1s, with a second generation — eloralintide, petrelintide, and peers — designed specifically for that lane (PMID 41747885). Eloralintide’s distinctive entry in that comparison is the fatigue column, which GLP-1 trial tables don’t feature at anything like 43–46%. For the GLP-1 side of the ledger, start with our retatrutide primer.

Where the Trial Data Stops: The Research-Vial Reality

Everything above describes pharmaceutical-grade LY3841136, manufactured by Eli Lilly, dosed under supervision. A lyophilized vial from a research-chemical storefront shares a molecule name with that product and nothing else that’s verifiable without testing — and eloralintide’s grey-market supply chain is weeks-to-months old, the stage at which quality is historically at its worst. The gap shows up three ways: identity and purity (a batch-matched COA is the only evidence the vial contains dose-accurate eloralintide), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer — our peptide calculator handles the math and deliberately nothing else), and no medical monitoring, which is the invisible ingredient in every trial safety table. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

Eloralintide is about as new as a research-market compound gets — its phase 2 was published in late 2025 — which means listings are appearing faster than documentation. The checklist doesn’t change: batch-matched COA naming the compound and quantity, independent third-party testing with a verifiable report number, and hard skepticism toward any listing quoting the Lancet trial’s 20% figure as if it applied to the vial. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like, and our guide library covers verification in depth. We don’t yet track live eloralintide prices; when our tested vendors stock it, this section gets the live table.

US Regulatory Status

Eloralintide is an investigational compound: not FDA-approved anywhere as of this writing, with Eli Lilly running later-stage development on the strength of the phase 2 results. Practically, that means no prescription version exists to compare against, every vial in circulation is research-market material sold for non-human research use, and no regulator has evaluated any of those products for identity, purity, or the safety profile described above. When approval status changes, this section changes with it.

PERSONAL OBSERVATION — PI EDITORIAL

We’ve watched this exact movie before: a Lancet paper lands, a compound’s search volume goes vertical, and within weeks research sites list vials at prices that assume the buyer read the headline but not the methods section. With eloralintide the gap is unusually wide — the trial compound was made by one of the most audited manufacturing operations on earth, and the vial is made by whoever got a synthesis order in fastest. Until third-party test results on market product start circulating, the COA is the only sentence of this page that applies to the one in your hand.

The rest of the amylin lineage now has its own breakdown: petrelintide side effects and amycretin side effects — and for the GLP-1 side of the stacking question, retatrutide side effects.

Frequently Asked Questions

What are the most common eloralintide side effects?

Nausea and fatigue. In the 48-week phase 2 trial, nausea affected 11–64% of participants depending on dose (vs 14% on placebo) and fatigue 0–46% (vs 12% placebo). In the 12-week phase 1, GI effects were infrequent — nausea 8%, diarrhea 10% — and decreased appetite (19%) led the table.

Does eloralintide cause less nausea than other weight-loss drugs?

That’s its design goal — it selectively targets amylin receptors, and in rats it caused less taste avoidance than cagrilintide. The phase 1’s 8% nausea rate supports the thesis at lower exposures; at the phase 2’s top doses, nausea still reached 25–64%. No head-to-head human trial has settled the comparison.

Does eloralintide cause fatigue?

Yes — it’s the second most common adverse event, and it climbs with dose: 0% at 1mg up to 43–46% at the 9mg exposure levels, versus 12% on placebo. Fatigue at that frequency is the clearest thing separating eloralintide’s profile from the GLP-1 family’s.

How much weight did people lose on eloralintide in trials?

Averages ranged from 9% (1mg) to 20% (9mg and 6→9mg) over 48 weeks, versus 0.4% on placebo, in the 263-person phase 2. The higher doses that produced 18–20% loss also produced the higher nausea and fatigue rates — effect and side effect climbed together.

Is eloralintide safe?

In trials it was “generally well tolerated”: most adverse events mild to moderate, no deaths, and one serious event judged unrelated to the drug in the phase 1 — in screened, monitored populations using pharmaceutical-grade product over at most 48 weeks. No equivalent safety data exists for research-market vials, which is a different question the trials cannot answer.

Can you stack eloralintide with retatrutide or tirzepatide?

No published human trial has tested eloralintide in any combination. Every published safety number comes from eloralintide alone; any stack’s side-effect profile is unmeasured. The nearest documented analogy — cagrilintide plus semaglutide — roughly doubled GI event rates versus monotherapy.

Glossary of Terms

  • Amylin: a pancreatic hormone co-released with insulin that signals fullness; eloralintide is a selective long-acting analogue.
  • LY3841136: Eli Lilly’s development code for eloralintide — the name used in early papers and trial registries.
  • Selective agonist: a compound that preferentially activates one receptor subtype — here, amylin receptor 1 over the calcitonin and amylin 3 receptors.
  • Adverse event (AE): any unwanted medical occurrence during a trial, related to the drug or not; placebo groups report them too.
  • Dose escalation: raising doses stepwise so tolerance develops — the phase 2 tested 3→9mg and 6→9mg schedules against fixed doses.
  • Conditioned taste avoidance: the rat behavior used as an animal proxy for nausea; eloralintide produced less of it than cagrilintide.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.

References